Skip to main content
logo
Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
65.82
+2.29 (3.60%)
Apr 6, 2026, 12:03 PM EDT - Market open

Inhibrx Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1.30.21.82.197.23
Revenue Growth (YoY)
550.00%-88.89%-17.88%-69.69%-43.89%
Gross Profit
1.30.21.82.197.23
Selling, General & Admin
23.3127.9129.3821.1212.36
Research & Development
113.03203.74191.64110.1971.44
Total Operating Expenses
136.33331.65221.02131.3183.8
Operating Income
-135.03-331.45-219.22-129.12-76.56
Interest Income
-10.9411.922.07-
Interest Expense
--13.49-31.84-18.18-5.22
Other Non-Operating Income (Expense)
-2,022-0.5800.01
Total Non-Operating Income (Expense)
-5.032,019-20.5-16.11-5.2
Pretax Income
-140.051,688-239.72-145.22-81.77
Provision for Income Taxes
00000
Net Income
-140.061,688-243-145.23-81.77
Minority Interest in Earnings
--1.63--
Net Income to Common
-140.061,688-243-145.23-81.77
Shares Outstanding (Basic)
1515124038
Shares Outstanding (Diluted)
1515124038
Shares Change (YoY)
3.36%27.17%-70.62%5.52%50.47%
EPS (Basic)
-9.04114.01-20.48-3.62-2.15
EPS (Diluted)
-9.04112.62-20.48-3.62-2.15
Shares Outstanding
14.5814.4847.3743.5638.99
Free Cash Flow
-129.83-197.01-197.9-115.99-81.19
Free Cash Flow Per Share
-8.38-13.15-16.80-2.89-2.14
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Operating Margin
-10386.54%-165724.00%-12178.94%-5890.37%-1058.83%
Profit Margin
-10773.46%843786.00%-13408.94%-6625.27%-1130.80%
FCF Margin
-9986.54%-98503.00%-10994.56%-5291.38%-1122.76%
EBITDA
-132.54-329.16-218.03-127.89-75.37
EBITDA Margin
-10195.54%-164581.50%-12112.78%-5834.49%-1042.30%
EBIT
-135.03-331.45-219.22-129.12-76.56
EBIT Margin
-10386.54%-165724.00%-12178.94%-5890.37%-1058.83%
Effective Tax Rate
-0.00%0.00%-0.00%-0.00%-0.00%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q